Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Jung K-W, Won Y-J, Kang MJ, Kong H-J, Im J-S, Seo HG. Prediction of cancer incidence and mortality in Korea, 2022. Cancer Res Treat. 2022;54(2):345–51.

Article  PubMed  PubMed Central  Google Scholar 

Wu S-G, Wang J, Sun J-Y, He Z-Y, Zhang W-W, Zhou J. Real-world impact of survival by period of diagnosis in epithelial ovarian cancer between 1990 and 2014. Front Oncol. 2019;9:639.

Article  PubMed  PubMed Central  Google Scholar 

Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. New Engl J Med. 2011;365(26):2473–83.

Article  CAS  PubMed  Google Scholar 

Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–96.

Article  CAS  PubMed  Google Scholar 

Hao J, Liu Y, Zhang T, He J, Zhao H, An R, et al. Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials. Crit Rev Oncol Hematol. 2021;157: 103145.

Article  PubMed  Google Scholar 

McCabe N, Turner NC, Lord CJ, Kluzek K, Białkowska A, Swift S, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly (ADP-ribose) polymerase inhibition. Cancer Res. 2006;66(16):8109–15.

Article  CAS  PubMed  Google Scholar 

Valerie K, Povirk LF. Regulation and mechanisms of mammalian double-strand break repair. Oncogene. 2003;22(37):5792–812.

Article  CAS  PubMed  Google Scholar 

Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274–84.

Article  CAS  PubMed  Google Scholar 

Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382–92.

Article  CAS  PubMed  Google Scholar 

Moore K, Colombo N, Scambia G, Kim B-G, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495–505.

Article  CAS  PubMed  Google Scholar 

González-Martín A, Pothuri B, Vergote I, DePont CR, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391–402.

Article  PubMed  Google Scholar 

Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154–64.

Article  CAS  PubMed  Google Scholar 

Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, McNeish IA, Swisher EM, et al. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. Gynecol Oncol. 2017;147(2):267–75.

Article  CAS  PubMed  Google Scholar 

Kim L, Kim J-A, Kim S. A guide for the utilization of health insurance review and assessment service national patient samples. Epidemiol Health. 2014;36.

Association WM. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–4.

Article  Google Scholar 

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453–7.

Article  Google Scholar 

Arend RC, O’Malley DM, Banerjee S, McLaurin K, Davidson R, Long GH. Utilization of poly(ADP-Ribose) polymerase inhibitors in ovarian cancer: a retrospective cohort study of US healthcare claims data. Adv Ther. 2022;39(1):328–45.

Article  CAS  PubMed  Google Scholar 

Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin. 2009;25(9):2303–10.

Article  PubMed  Google Scholar 

Berek J, Matulonis U, Peen U, Ghatage P, Mahner S, Redondo A, et al. Safety and dose modification for patients receiving niraparib. Ann Oncol. 2018;29(8):1784–92.

Article  CAS  PubMed  Google Scholar 

Ni J, Cheng X, Zhao Q, Dai Z, Xu X, Guo W, et al. The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China. J Ovarian Res. 2021;14:1–9.

Article  Google Scholar 

Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Family Phys. 2007;76(3):391–6.

Google Scholar 

Zhang Z-Y, Kansra V, Van Andel L, Tibben M, Rosing H, Lu S, et al. Characterization of absorption, metabolism, and elimination of Niraparib, an investigational poly (ADP-ribose) polymerase inhibitor, in cancer patients. Clin Ther. 2017;39(8):e7–8.

Article  Google Scholar 

González-Martín A, Pothuri B, Vergote I, Graybill W, Lorusso D, McCormick CC, et al. Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer. Eur J Cancer. 2023;189: 112908.

Article  PubMed  Google Scholar 

Gale R. Myelosuppressive effects of antineoplastic chemotherapy. In: Testa NG, Gale RP, editors. Hematopoiesis: long-term effects of chemotherapy and radiation. Marcel Dekker Inc. 1988. p. 63–73.

Marques M, Beauchamp MC, Fleury H, Laskov I, Qiang S, Pelmus M, et al. Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors. BMC Med. 2015;13:217.

Article  PubMed  PubMed Central  Google Scholar 

Farrés J, Martín-Caballero J, Martínez C, Lozano JJ, Llacuna L, Ampurdanés C, et al. Parp-2 is required to maintain hematopoiesis following sublethal γ-irradiation in mice. Blood. 2013;122(1):44–54.

Article  PubMed  Google Scholar 

Shah A, Shah R, Kebede N, Mohamed A, Botteman M, Waldeck R, et al. Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy. J Med Econ. 2020;23(4):330–46.

Article  PubMed  Google Scholar 

Pal S, Gong J, Mhatre SK, Lin S-W, Surinach A, Ogale S, et al. Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database. BMC Cancer. 2019;19(1):1–15.

Article  CAS  Google Scholar 

Hansen RN, Hackshaw MD, Nagar SP, Arondekar B, Deen KC, Sullivan SD, et al. Health care costs among renal cancer patients using pazopanib and sunitinib. J Manag Care Spec Pharm. 2015;21(1):37–44.

PubMed  Google Scholar 

Hansen RN, Ramsey SD, Lalla D, Masaquel A, Kamath T, Brammer M, et al. Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens. Springerplus. 2014;3:1–8.

Article  Google Scholar 

Burns EM, Rigby E, Mamidanna R, Bottle A, Aylin P, Ziprin P, et al. Systematic review of discharge coding accuracy. J Public Health. 2012;34(1):138–48.

Article  CAS  Google Scholar 

Lee J, Lee JS, Park S-H, Shin SA, Kim K. Cohort profile: the national health insurance service–national sample cohort (NHIS-NSC), South Korea. Int J Epidemiol. 2017;46(2): e15-e.

Google Scholar 

Lee J-Y, Kim K, Lee YS, Kim HY, Nam EJ, Kim S, et al. Treatment preferences of advanced ovarian cancer patients for adding bevacizumab to first-line therapy. Gynecol Oncol. 2016;143(3):622–7.

Article  CAS  PubMed  Google Scholar